PD‐L1 (CD274) expression is a biomarker for selecting NSCLC patients for pembrolizumab treatment.37, 38 Therefore, PD‐L1 expression was investigated in patients stratified by the immune prognostic model. The gene discussed is CD274; the disease is non-small cell lung carcinoma.